MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery

• Published in: International journal of molecular sciences Vol. 23; no. 24; p. 15825
• Main Authors: Kalinowski, Piotr, Smyk, Wiktor, Nowosad, Małgorzata, Paluszkiewicz, Rafał, Michałowski, Łukasz, Ziarkiewicz-Wróblewska, Bogna, Weber, Susanne N, Milkiewicz, Piotr, Lammert, Frank, Zieniewicz, Krzysztof, Krawczyk, Marcin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.12.2022; MDPI
• Subjects: 17-Hydroxysteroid Dehydrogenases - genetics; Acyltransferase; Alleles; Bariatric Surgery; Biopsy; Body mass index; Cirrhosis; Diabetes; Domains; Fatty liver; Fibrosis; Gastrectomy; Gastrointestinal surgery; Genetic diversity; Genetic Predisposition to Disease; Genotyping; Health risk assessment; Humans; Hydroxysteroids; Hyperlipidemia; Laparoscopy; Liver; Liver - pathology; Liver cancer; Liver cirrhosis; Liver Cirrhosis - pathology; Liver diseases; liver fibrosis; Metabolism; Mitochondria; mitochondrial amidoxime-reducing component 1; Mitochondrial Proteins - genetics; Multivariate analysis; NAFLD; NASH; Non-alcoholic Fatty Liver Disease - genetics; Non-alcoholic Fatty Liver Disease - pathology; Oxidoreductases - genetics; Polymorphism; Polymorphism, Single Nucleotide; Risk factors; Steatosis; Surgery; Triglycerides; weight-loss surgery; mitochondrial amidoxime-reducing component 1; NAFLD; liver fibrosis; weight-loss surgery; NASH
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232415825

The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 ( ) rs738409, transmembrane 6 superfamily member 2 ( ) rs58542926, and membrane-bound O-acyltransferase domain containing 7 ( ) rs641738. Recently, mitochondrial amidoxime reducing component 1 ( ) rs2642438 and hydroxysteroid 17-beta dehydrogenase 13 ( ) rs72613567 polymorphisms were shown to have protective effects on liver diseases. Here, we evaluate these variants in patients undergoing bariatric surgery. A total of 165 patients who underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies and 314 controls were prospectively recruited. Genotyping was performed using TaqMan assays. Overall, 70.3% of operated patients presented with hepatic steatosis. NASH (non-alcoholic steatohepatitis) was detected in 28.5% of patients; none had cirrhosis. The increment of liver fibrosis stage was associated with decreasing frequency of the minor allele ( = 0.03). In multivariate analysis was an independent protective factor against fibrosis ≥ 1b (OR = 0.52, = 0.03) and ≥ 1c (OR = 0.51, = 0.04). The risk allele was associated with increased hepatic steatosis, fibrosis, and NASH (OR = 2.22, = 0.04). The polymorphism was protective against liver injury as reflected by lower AST ( = 0.04) and ALT ( = 0.03) activities. The polymorphism was associated with increased ALT ( = 0.04). In conclusion, hepatic steatosis is common among patients scheduled for bariatric surgery, but the and polymorphisms lower liver injury in these individuals.